THYROID CANCERS

Lung Cancer

Lung Cancer

Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with&nbsp;relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission.&nbsp;<br /> &nbsp;

Lori J. Wirth, MD, discusses the era of precision genotype targeted therapy in advanced thyroid cancer, with a focus on individual targets in subtypes of thyroid cancer.&nbsp;

BGB-283, a novel agent that targets <em>RAS/RAF</em>-mutated tumors, demonstrated activity across a variety of tumor types, according to the results of a preliminary clinical evaluation presented at the 2017 AACR Annual Meeting.

A study presented at the 2017 Cancer Survivorship Symposium revealed a long-term cardiovascular risk associated with administration of levothyroxine.

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Jochen H. Lorch, MD, MS&nbsp;discusses&nbsp;current approved treatment options for patients with MTC, the biology of the disease, managing potential progression, and future possibilities in the treatment of MTC.

With anaplastic thyroid cancer (ATC) being a rare disease that often has poor prognoses, researchers are seeking therapies for these patients that are more promising than surgery or radiation.

William Cance, MD, has recently joined the University of Arizona Cancer Center (UACC) as Deputy Director.

Targeting NTRK fusions is a new treatment option being explored for patients with papillary thyroid cancer.&nbsp;

Pembrolizumab (Keytruda) demonstrated promising antitumor activity with durable responses in patients with advanced thyroid cancer, according to results from the KEYNOTE-028 trial presented at the 2016 ASCO Annual Meeting. The overall response rate (ORR) with the PD-1 inhibitor was 9.1%, which included 2 partial responses (PR).

Infusion with 19-28z chimeric antigen receptor (CAR) modified T-cells led to complete response (CR) rates of 77% to 90% and minimal residual disease (MRD)-CR rates of 68% to 70% in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL).

Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.

In recent years, significant advancements have been made in the field of thyroid cancer.

Sue Naeyaert, senior director of Biosimilars Policy, EMD Serono, discusses the long-term impact that biosimilars could potentially have on the field of oncology.

The multikinase inhibitor lenvatinib (Lenvima) has quickly become the frontline standard of care for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), just one year following its initial approval, according to Renato Martins, MD.

Bible says most oncologists would consider lenvatinib as a first-line therapy for patients who require systemic therapy where there are not suitable, focal palliative options.

Cabanillas says her and her team set a goal of reducing the time between when they are contacted about a patient with anaplastic thyroid cancer, and when the patient is given an appointment time, to fewer than 5 business days.